LUXBreast1_2 | R Documentation |
Kaplan-Meier digitized data from LUXBreast1, figure 2 (PMID 26822398). A reported sample size of 508 for a primary endpoint of PFS in breast cancer.
LUXBreast1_2
A data frame of 508 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (afatinib, t) | |
Harbeck N, Huang C-S, Hurvitz S, et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol 2016; 17: 357–66.
summary(LUXBreast1_2)
kmplot(LUXBreast1_2)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.